)
Processa Pharmaceuticals (PCSA) investor relations material
Processa Pharmaceuticals Company presentation summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Transaction and capital
Vidya’s equity was exchanged for common stock and newly created Series A non-voting convertible preferred stock in a sign-and-close reverse merger.
A concurrent $200M PIPE is designated for pipeline advancement, working capital and general corporate purposes; pro forma runway is expected into 2029, through multiple clinical milestones.
Expected capitalization after Series A conversion: 2.8M common shares plus 306.6M as-converted preferred shares, totaling 309.4M; subject to stockholder approval and beneficial ownership limits.
VT7208
Potentially best-in-class, once-daily oral BTK inhibitor with preclinical potency, peripheral and CNS target engagement, and consistent efficacy across disease models.
Phase 1 showed favorable safety and tolerability across evaluated doses, with no dose-limiting toxicities, serious adverse events, treatment-related discontinuations, liver safety signal or bleeding-related events.
Median half-life was ~6 hours, supporting once-daily dosing; exposure increased near dose-proportionally and BTK occupancy remained ≥95% for 48 hours after the last dose.
Phase 2 initiation and proof-of-concept data targeted: food allergy H2 2026 and H2 2027; CSU H2 2026 and H1 2028; relapsing MS H1 2027 and H2 2028.
Oral FcRn program
Research collaboration and exclusive option with Generian Pharmaceuticals covers a macrocyclic peptide against the clinically validated FcRn target; work is in lead optimization through development-candidate nomination.
FcRn blockade directs pathogenic IgG, including autoantibodies, to degradation; the mechanism may address IgG-driven diseases including MG, CIDP, ITP and wAIHA.
VYVGART generated $4.15B in 2025 global net sales, up 90% vs. 2024; development-candidate nomination for the oral program is targeted for 2H 2027.
- Vidya expands the pipeline, but acquisition accounting drove a $183.2M Q3 loss.PCSA
Q3 2026 - Vidya deal funds three planned Phase 2 programs into H2 2029, pending key votes.PCSA
Proxy filing - VT-7208’s Phase 2 strategy is funded into 2H 2029, pending key shareholder votes.PCSA
Proxy filing - A reverse split vote is a key step toward Nasdaq listing and a later preferred-conversion vote.PCSA
Proxy filing - Merger and $200 million PIPE set up major conversion dilution and five critical stockholder votes.PCSA
Proxy filing - Reverse split approval is pivotal to Nasdaq listing and preferred-share conversion.PCSA
Proxy filing - A 306.6 million-share resale registration accompanies the shift to VT-7208-led development.PCSA
Registration filing - Merger and $200M PIPE fund VT-7208, a promising BTK inhibitor, into Phase 2 trials.PCSA
Company presentation - Parallel phase II trials for a novel BTK inhibitor are funded through 2029, with key data in 2027–2028.PCSA
H.C. Wainwright 28th Annual Global Investment Conference
)
)
)
)
)
)
)
)